Next Article in Journal
Small-Cell Lung Cancer: Is the Black Box Finally Opening Up?
Next Article in Special Issue
HER2-Positive Breast Cancer Patients with Pre-Treatment Axillary Involvement or Postmenopausal Status Benefit from Neoadjuvant Rather than Adjuvant Chemotherapy Plus Trastuzumab Regimens
Previous Article in Journal
Tumor Microenvironment Features as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors (ICI) in Metastatic Clear Cell Renal Cell Carcinoma (mccRCC)
Previous Article in Special Issue
The Prognostic Value of Lymph Node Involvement after Neoadjuvant Chemotherapy Is Different among Breast Cancer Subtypes
Open AccessArticle

The Presence of an In Situ Component on Pre-Treatment Biopsy Is Not Associated with Response to Neoadjuvant Chemotherapy for Breast Cancer

1
Department of Surgery, Institut Curie, 75005 Paris, France
2
Department of Gynecology and Obstretrics, Hôpitaux Universitaires de Genève, 1205 Geneva, Switzerland
3
Medical Oncology Department, Centre René Hughenin, 92210 Saint Cloud, France
4
Department of Tumor Biology, Institut Curie, 75005 Paris, France
5
Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, 75248 Paris, France
*
Author to whom correspondence should be addressed.
Cancers 2021, 13(2), 235; https://doi.org/10.3390/cancers13020235
Received: 12 November 2020 / Revised: 25 December 2020 / Accepted: 6 January 2021 / Published: 10 January 2021
(This article belongs to the Special Issue Neoadjuvant Systemic Therapy in Early Breast Cancer)
Identifying markers predictive of response and resistance to neoadjuvant chemotherapy (NAC) has become a major research objective. Ductal carcinoma in situ (DCIS) is associated with invasive disease in more than half of invasive breast cancer cases. It is generally assumed that DCIS does not respond to NAC, but the effect of chemotherapy on in situ components has been little studied. We assessed the predictive value of the presence of an in situ component on pre-NAC biopsy on pathological complete response (pCR) in a real-life cohort of patients treated by NAC. We included 1148 patients; 44% of tumors were luminal (n = 508), 31% triple negative breast cancer (TNBC) (n = 359) and 24% HER2-positive (n = 281). DCIS was found in 225 samples (19.6%) before NAC. The presence of a DCIS component on pre-NAC biopsy was not associated with pCR and did not seem to be a critical factor for the prediction of response to NAC.
A ductal in situ (DCIS) component is often associated with invasive breast carcinoma (BC), and its effect on response to treatment is unknown. We assessed the predictive value of the DCIS component for pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC). We analyzed a cohort of 1148 T1–3NxM0 breast cancer (BC) patients treated by NAC at Institut Curie between 2002 and 2012. The presence of a DCIS component was retrospectively recorded from both the pre-NAC biopsy pathological report and surgical specimens. We included 1148 BC patients treated by NAC for whom pre- and post-NAC data concerning the in situ component were available. DCIS was present before NAC in 19.6% of the population. Overall, 283 patients (19.4%) achieved pCR after NAC. There was no significant association between the presence of DCIS on pre-NAC biopsy and pCR. In a multivariate analysis including subtype, tumor size, grade, mitotic index, and Ki67 index, only BC subtype (luminal/TNBC/HER2-positive) and Ki67 were significantly associated with pCR. The presence of a DCIS component on pre-NAC biopsy is not associated with pCR and does not seem to be a critical factor for predicting response to NAC. View Full-Text
Keywords: breast cancer; neoadjuvant chemotherapy (NAC); ductal carcinoma in situ (DCIS); pathological complete response (pCR) breast cancer; neoadjuvant chemotherapy (NAC); ductal carcinoma in situ (DCIS); pathological complete response (pCR)
Show Figures

Figure 1

MDPI and ACS Style

Labrosse, J.; Morel, C.; Lam, T.; Laas, E.; Feron, J.-G.; Coussy, F.; Lae, M.; Reyal, F.; Hamy, A.-S. The Presence of an In Situ Component on Pre-Treatment Biopsy Is Not Associated with Response to Neoadjuvant Chemotherapy for Breast Cancer. Cancers 2021, 13, 235. https://doi.org/10.3390/cancers13020235

AMA Style

Labrosse J, Morel C, Lam T, Laas E, Feron J-G, Coussy F, Lae M, Reyal F, Hamy A-S. The Presence of an In Situ Component on Pre-Treatment Biopsy Is Not Associated with Response to Neoadjuvant Chemotherapy for Breast Cancer. Cancers. 2021; 13(2):235. https://doi.org/10.3390/cancers13020235

Chicago/Turabian Style

Labrosse, Julie; Morel, Charlotte; Lam, Thanh; Laas, Enora; Feron, Jean-Guillaume; Coussy, Florence; Lae, Marick; Reyal, Fabien; Hamy, Anne-Sophie. 2021. "The Presence of an In Situ Component on Pre-Treatment Biopsy Is Not Associated with Response to Neoadjuvant Chemotherapy for Breast Cancer" Cancers 13, no. 2: 235. https://doi.org/10.3390/cancers13020235

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop